In this issue:
Adjuvant ipilimumab vs high-dose interferon alfa-2b for resected high-risk melanoma
Long-term outcomes and responses to retreatment in patients with melanoma treated with PD-1 blockade
Encorafenib plus binimetinib vs vemurafenib or encorafenib in patients with BRAF V600–mutant melanoma
Intracranial antitumor activity with encorafenib + binimetinib in patients with melanoma
QoL assessment in French patients with metastatic melanoma
QoL in patients with fully resected BRAFV600 mutation–positive melanoma receiving adjuvant vemurafenib
Adjuvant dabrafenib + trametinib vs placebo in patients with resected, BRAFV600-mutant, stage III melanoma
Cumulative incidence and predictors of CNS metastasis for patients with stage III melanoma
Accuracy of computer-aided diagnosis of melanoma
Please login below to download this issue (PDF)